Abstract:Antibody–drug conjugates (ADCs) are an innovative family of agents assembled through linking cytotoxic drugs (payloads) covalently to monoclonal antibodies (mAbs) to be delivered to tumor tissue that express their particular antigen, with the theoretical advantage of an augmented therapeutic ratio. As of June 2023, eleven ADCs have been approved by the Food and Drug Administration (FDA) and are on the market. These drugs have been added to the therapeutic armamentarium of acute myeloblastic and lymphoblastic leukemias, various types of lymphoma, breast, gastric or gastroesophageal junction, lung, urothelial, cervical, and ovarian cancers. They have proven to deliver more potent and effective anti-tumor activities than standard practice in a wide variety of indications. In addition to targeting antigen-expressing tumor cells, bystander effects have been engineered to extend cytotoxic killing to low-antigen-expressing or negative tumor cells in the heterogenous tumor milieu. Inevitably, myelosuppression is a common side effect with most of the ADCs due to the effects of the cytotoxic payload. Also, other unique side effects are specific to the tissue antigen that is targeted for, such as the cardiac toxicity with Her-2 targeting ADCs, and the hemorrhagic side effects with the tissue factor (TF) targeting Tisotumab vedotin. Further exciting developments are centered in the strategies to improve the tolerability and efficacy of the ADCs to improve the therapeutic window; as well as the development of novel payloads including (1) peptide–drug conjugates (PDCs), with the peptide replacing the monoclonal antibody, rendering greater tumor penetration; (2) immune-stimulating antibody conjugates (ISACs), which upon conjugation of the antigen, cause an influx of pro-inflammatory cytokines to activate dendritic cells and harness an anti-tumor T-cell response; and (3) the use of radioactive isotopes as a payload to enhance cytotoxic activity.

Comprehensive review on the elaboration of payloads derived from natural products for antibody-drug conjugates

Natural-source payloads used in the conjugated drugs architecture for cancer therapy: Recent advances and future directions

Antibody-Drug Conjugates Containing Payloads from Marine Origin

Antibody Drug Conjugates for Cancer Therapy: From Metallodrugs to Nature-Inspired Payloads

Payload diversification: a key step in the development of antibody–drug conjugates

Homogeneous multi-payload antibody–drug conjugates

Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy

CHAPTER 2. Design Factors Important for Antibody–Drug Conjugate (ADC) Payloads

Exploring the next generation of antibody–drug conjugates

Antibody-drug conjugates: recent advances in conjugation and linker chemistries

Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry

Development of antibody-drug conjugates in cancer: Overview and prospects

Present Scenario and Future Landscape of Payloads for ADCs: Focus on DNA-Interacting Agents

Exploring the Sensitivity of Antibody-Drug Conjugate Efficacy to the Selection of Payload, Antibody, and Cell line

Natural Product Bis-Intercalator Depsipeptides as a New Class of Payloads for Antibody-Drug Conjugates

The Evolution of Antibody‐Drug Conjugates: Toward Accurate DAR and Multi‐specificity

The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads

Research progress on novel antibody drug conjugates in cancer therapy

Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies

Design and evaluation of ZD06519, a novel camptothecin payload for antibody drug conjugates

Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence